Sheridan – October 13, 2026 -- The global sensor patch market is valued at USD 7.9 billion in 2026 and is projected to reach USD 28.9 billion by 2031, a CAGR of 29.6%, according to a study by Wissen Research.
Chronic disease burden drives demand for remote monitoring
Sensor patches are adhesive, skin-worn devices that measure signals such as glucose, cardiac activity, and temperature and transmit the data wirelessly to a smartphone, cloud platform, or clinician. The World Health Organization links chronic disease to about 41 million deaths a year, roughly 71% of all deaths worldwide. The International Diabetes Federation estimates that about 589 million adults aged 20-79 had diabetes in 2024.
As care shifts to remote and home settings, continuous glucose monitoring (CGM) and ambulatory cardiac patches are becoming core tools for managing long-term conditions outside the clinic.
Abbott, DexCom and iRhythm announce moves in 2026
In June 2026, DexCom received FDA clearance to extend its Stelo biosensor to children aged 2 and older who do not use insulin. It also announced a redesigned app and planned expansion into the U.K., Australia, New Zealand, and South Korea.
In May 2026, Abbott secured CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone wearables offering up to 15 or 10 days of wear. European launches are planned later in 2026.
In April 2026, iRhythm Technologies agreed to acquire VitalConnect for approximately USD 287.5 million. The deal combines iRhythm's Zio cardiac monitoring service with VitalConnect's VitalPatch biosensor, which delivers real-time ECG and vital-sign data through cloud connectivity, and expands iRhythm's hospital and remote-care reach.
Glucose and ECG patches lead; multimodal sensing remains in validation
Glucose and ECG patches are the commercially mature applications. Development is focused on temperature, blood pressure, hydration, metabolism, and biochemical sensing. Many multimodal systems remain at various stages of validation rather than mass-market maturity.
Longer-wear products such as Dexcom's G7 15 Day and Senseonics' Eversense 365 reflect the push toward fewer sensor replacements.
Amperometric technology and bodywear hold largest segment shares
Amperometric technology held the largest share by technology type in 2025, supported by CGM scale. Abbott reports about 7 million FreeStyle Libre users worldwide and USD 6.8 billion in 2024 diabetes care revenue. DexCom reported USD 4.662 billion in 2025 revenue, up 16% from 2024, and about 3.5 million customers at year-end 2025.
Bodywear, with sensors worn on the upper arm and torso, held the largest share by wearable type. iRhythm reported USD 747.1 million in 2025 revenue, up 26.2%, on growing Zio volume.
North America leads while Asia Pacific grows fastest
North America held the largest regional share in 2025, backed by developed healthcare infrastructure, digital health adoption, a favorable regulatory framework, and the presence of leading CGM and cardiac monitoring companies. Asia Pacific is the fastest-growing region; the report covers China, Japan, India, Australia and New Zealand, and South Korea.
The market is moderately consolidated in CGM and ambulatory cardiac monitoring but fragmented across emerging sensing technologies. Competition there turns on accuracy, clinical validation, wear duration, connectivity, and manufacturing scale.
Accuracy over long wear and regulation remain hurdles
Maintaining accuracy over long wear periods is the main technical challenge. Signal drift, calibration, biofouling, skin adhesion, battery life, and mechanical deformation all affect performance. Newer biochemical and multimodal applications still need clinical validation, scaled-up manufacturing, better calibration, and clearer regulatory frameworks. Connected devices must also address data security and interoperability across healthcare systems.